K
Kathryn N. Kurtzman
Researcher at Pharmaceutical Product Development
Publications - 18
Citations - 484
Kathryn N. Kurtzman is an academic researcher from Pharmaceutical Product Development. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 7, co-authored 12 publications receiving 145 citations.
Papers
More filters
Journal ArticleDOI
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Eric A. Klein,Donald A. Richards,Allen Lee Cohn,M.K. Tummala,Rosanna Lapham,David Cosgrove,G. Chung,Jessica M. Clement,Jianjun Gao,Nathan Hunkapiller,Arash Jamshidi,Kathryn N. Kurtzman,Michael V. Seiden,Charles Swanton,Minetta C. Liu +14 more
TL;DR: In this article, a multi-cancer early detection (MCED) test was proposed to detect cancer signals across multiple cancer types and predict cancer signal origin (CSO) with high accuracy.
Journal ArticleDOI
Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.
Eric A. Klein,Earl Hubbell,Tara Maddala,Alex Aravanis,John F. Beausang,Darya Filippova,Samuel Gross,Arash Jamshidi,Kathryn N. Kurtzman,Ling Shen,Anton Valouev,Oliver Venn,Nan Zhang,David Smith,Timothy J. Yeatman,Robert Tibshirani,Richard Thomas Williams,Anne-Renee Hartman,Michael V. Seiden,Minetta C. Liu +19 more
TL;DR: CCGA is a prospective multi-center observational study for development of a noninvasive cfDNA-based multi-cancer detection assay detecting multiple cancers at early stages when curative treatment is more likely to succeed.
Journal ArticleDOI
Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA.
Xiaoji Chen,Zhao Dong,Earl Hubbell,Kathryn N. Kurtzman,Geoffrey R. Oxnard,Venn Oliver Claude,Collin Melton,Christina A. Clarke,Rita Shaknovich,Ting Ma,Gerry Meixiong,Michael V. Seiden,Eric A. Klein,Eric T. Fung,Minetta C. Liu +14 more
TL;DR: In this article, the authors evaluated the prognostic significance of cancer detection by the MCED test using longitudinal follow-up data and found that MCED was prognostic beyond clinical stage and method of diagnosis.
Journal ArticleDOI
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Arash Jamshidi,Minetta C. Liu,Eric A. Klein,Oliver Venn,Earl Hubbell,John F. Beausang,Samuel Gross,Collin Melton,Alexander P. Fields,Qinwen Liu,N. Zhang,Eric T. Fung,Kathryn N. Kurtzman,Hamed Amini,Craig Betts,Daniel Civello,Peter Freese,Robert T. Calef,Konstantin Davydov,Saniya Fayzullina,Chenlu Hou,Roger Jiang,Byoungsok Jung,Susan Tang,Vasiliki Demas,Joshua Newman,Onur Sakarya,Eric Scott,Archana Shenoy,Seyed Pouzhia Shojaee,Kristan K. Steffen,Virgil Nicula,Tom C. Chien,Siddhartha Bagaria,Nathan M. Hunkapiller,Mohini B. Desai,Zhao Dong,A. Richards,Timothy J. Yeatman,Allen Lee Cohn,David Thiel,Donald A. Berry,Mohan K Tummala,Kristi McIntyre,Mikkael A. Sekeres,Alan Douglas Bryce,Alex Aravanis,Michael V. Seiden,Charles Swanton +48 more
TL;DR: In this article , the authors evaluated several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining clinical limit of detection (LOD) based on circulating tumor allele fraction (cTAF), enabling performance comparisons.
Journal ArticleDOI
Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
Minetta C. Liu,Tara Maddala,Alex Aravanis,Earl Hubbell,John F. Beausang,Darya Filippova,Samuel Gross,Arash Jamshidi,Kathryn N. Kurtzman,Ling Shen,Anton Valouev,Oliver Venn,Nan Zhang,David Smith,Fergus J. Couch,Christina Curtis,Richard Thomas Williams,Eric A. Klein,Anne-Renee Hartman,José Baselga +19 more
TL;DR: New breast cancer screening approaches are needed to detect clinically aggressive subtypes that may not be detected by mammography or are detected late in unscreened populations.